Albireo Pharma Inc Ret. on equity
What is the Ret. on equity of Albireo Pharma Inc?
The Ret. on equity of Albireo Pharma Inc is -97.59%
What is the definition of Ret. on equity?
Return on equity is a measure of the profitability of a business in relation to the book value of the shareholder equity. It is computed by dividing fiscal year net income by total shareholder equity.
ttm (trailing twelve months)
The return on equity (ROE) ROE is a measure of how well a company uses investments to generate earnings growth. ROE is used for comparing the performance of companies in the same industry. It indicated the management's ability to generate income from the equity available to it. ROEs of 15-20% are generally considered good. ROEs are also a factor in stock valuation, in association with other financial ratios. In general, stock prices are influenced by earnings per share (EPS), so that stock of a company with a 20% ROE will generally cost twice as much as one with a 10% ROE.
Ret. on equity of companies in the Health Care sector on NASDAQ compared to Albireo Pharma Inc
What does Albireo Pharma Inc do?
Albireo Pharma is a clinical-stage biopharmaceutical company focused on the development of novel bile acid modulators to treat rare pediatric and adult liver diseases, and other adult liver diseases and disorders. Albireo's lead product candidate, odevixibat, is being developed to treat rare pediatric cholestatic liver diseases with Phase 3 pivotal trials in PFIC, Alagille syndrome and biliary atresia. The Company completed IND-enabling studies for new preclinical candidate A3907 this year and plans to advance development in adult liver disease. Albireo was spun out from AstraZeneca in 2008 and is headquartered in Boston, Massachusetts, with its key operating subsidiary in Gothenburg, Sweden. The Boston Business Journal named Albireo one of the 2020 Best Places to Work in Massachusetts for the second consecutive year.
Companies with ret. on equity similar to Albireo Pharma Inc
- TCR2 Therapeutics has Ret. on equity of -97.81%
- Lianhua Supermarket Co has Ret. on equity of -97.68%
- ZEN Graphene Solutions has Ret. on equity of -97.65%
- Edison Nation has Ret. on equity of -97.62%
- Sierra Oncology Inc has Ret. on equity of -97.61%
- VIVO Cannabis has Ret. on equity of -97.59%
- Albireo Pharma Inc has Ret. on equity of -97.59%
- Goldcliff Resource has Ret. on equity of -97.54%
- iMedia Brands has Ret. on equity of -97.45%
- OXE Marine AB (publ) has Ret. on equity of -97.41%
- KalVista Pharmaceuticals Inc has Ret. on equity of -97.37%
- Pieris Pharmaceuticals Inc has Ret. on equity of -97.28%
- Alès e SA has Ret. on equity of -97.21%